<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Bramble: Sleep apnoea</title>
    <link>https://news.ketelle.co.uk/entities/sleep-apnoea</link>
    <description>Stories involving Sleep apnoea, told neutrally, with how each side covers them.</description>
    <language>en-gb</language>
    <atom:link href="https://news.ketelle.co.uk/entities/sleep-apnoea/feed.xml" rel="self" type="application/rss+xml"/>
    <item>
      <title>Eli Lilly's weight-loss pill Foundayo eases sleep apnoea in two late-stage trials</title>
      <link>https://news.ketelle.co.uk/stories/weight-loss-pill-studied-as-treatment-for-obstructive-sleep-apnoea</link>
      <guid isPermaLink="true">https://news.ketelle.co.uk/stories/weight-loss-pill-studied-as-treatment-for-obstructive-sleep-apnoea</guid>
      <pubDate>Mon, 09 Nov 2026 18:53:39 +0000</pubDate>
      <category>Health</category>
      <description>Two late-stage trials found Eli Lilly's once-daily pill Foundayo (orforglipron) reduced obstructive sleep apnoea severity in overweight or obese adults. The results were presented at the American Heart Association meeting and published in JAMA; Lilly plans to seek approval for the condition. (3 outlets: 1 left · 1 centre · 1 right)</description>
      <media:content url="https://i.dailymail.com/1s/2026/11/09/14/110545465-0-For_decades_the_gold_standard_treatment_for_obstructive_sleep_ap-a-10_1794233291521.jpg" medium="image"/>
    </item>
  </channel>
</rss>
